Browse > Article

Evaluation of p53 and Bax Expression as Prognostic Markers in Invasive Cervical Carcinoma Stage IIB Patients Treated with Radiation Therapy  

Choi Sukjin (Department of Pthology, Inha University Medical College)
Kim Hunjung (Department of Radiation Oncology, Inha University Medical College)
Song Eunseop (Department of Obstetrics and Gynecology, Inha University Medical College)
Kim Changyoung (Department of Obstetrics and Gynecology, Sam Hospital)
Lee Meejo (Department of Radiation Oncology, Inha University Medical College)
Kim Woochul (Department of Radiation Oncology, Inha University Medical College)
Loh John J. K. (Department of Radiation Oncology, Inha University Medical College)
Publication Information
Radiation Oncology Journal / v.23, no.2, 2005 , pp. 98-105 More about this Journal
Abstract
Purpose : The objective of our study was to evaluate the immunohistochemical expression of p53 and bax proteins as prognostic markers in FIGO stage IIb invasive squamous cell carcinoma of the uterine cervix. Materials and Methods : Sixty-five cases of squamous cell carcinoma of the cervix (stage IIb) that were diagnosed from October 1995 to December 2003 were analyzed retrospectively for the bax and p53 expression. These expressions were determined immunohistochemically and they were correlated to the patients' overall survival and disease-free survival. Results : The overall 5-year survival (OS) rate and the disease-free survival (DFS) rate were $65.1\%$ and $62.9\%$, respectively. p53 and bax immunoreactivity was seen in $26.2\%$ and $52.3\%$ of cases, respectively, with variable levels of expression. On the univariate analysis, only p53 positivity correlated with poor survival in DFS (log-rank test p=0.027), but this significance was not maintained on multivariated analysis by Cox's regression. The nine cases with the immunophenotype ps3+/bax- had the poorest survival. Conclusion : Neither p53 nor bax expression are Independent predictors of the prognosis for stage IIb cervical squamous cancers. Evaluation of p53 and bax co-expression may affect the clinical outcome and further investigation is needed.
Keywords
p53; Bax; Cervical carcinoma; Prognosis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Liang XH, Mungal S, Ayscue A, et al. Bcl-2 protooncogene expression in cervical carcinoma cell lines containing inactive p53. J Cell Biochem 1995:57:509-521   DOI   ScienceOn
2 Jaros E, Perry RH, Adam L, et al. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumors. Br J Cancer 1992;66:373-385   DOI   ScienceOn
3 Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200-206   DOI   PUBMED
4 Harris M, Metcalf RA, Welsh A, Montesano R, Harris CC. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Scc USA 1990;887:9958-9961
5 Harris CC. Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-1327   DOI   ScienceOn
6 l.ipponan P. Ji H. Aaltomaa S. Syrianen S. Syrianen K. p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer 1993;55:51-56   DOI   ScienceOn
7 Couture G. Raybaud-Diogene H. Tetu B. et al. p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer 2002;94:713-722   DOI   PUBMED   ScienceOn
8 Raikumar T. Haian S. Baruah RK. Majhi U. Selvaluxmi G. Vasanthan A. Prognostic significance of Bcl-2 and p53 protein expression in stage IIB and IIIB squamous cell carcinoma of the cervix. Eur J Gynaecol Oncol 1998;19:556-560
9 Jain D. Srinivasan R. Patel FD. Kumari Gupta S. Evaluation of p53 and Bcl-2 expression as prognostic markers in invasive cervical carcinoma stage IIb/III patients treated by radiotherapy. Gynecol Oncol 2003;88:22-28   DOI   ScienceOn
10 Dimitrakakis C. Kymionis G. Diakomanolis E. et al. The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions. Gynecol Oncol 2000;77:129-136   DOI   ScienceOn
11 Park TW. Fujiwara H. Wright TC. Molecular biology of cervical cancer and its precursors. Cancer 1995:76:1902-1913   DOI   PUBMED   ScienceOn
12 Chung TK. Cheung TH, Lo WK, et al. Expression of apoptotic regulators and their significance in cervical cancer. Cancer Lett 2002;180:63-68   DOI   ScienceOn
13 Korsmever SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992;80:879-886
14 Bubendorf L, Sauter G, Moch H, et al. Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am J Pathol 1996;148:1557-1565
15 Pillai MR. Jayacrakash PG. Nair MK. Bcl-2 immunoreactivity but not p53 accumulation associated with tumour response to radiotherapy in cervical carcinoma. J Cancer Res Clin Oncol 1999;125:55-60   DOI   ScienceOn
16 Wootipoom V. Lekhyananda N. Phungrassami T. Boonyaphiphat P. Thongsuksai P. Prognostic significance of Bax, Bcl-2, and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy. Gynecol Oncol 2004;94:636-642   DOI   ScienceOn
17 Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 1996;88:386-401
18 Marchetti A. Buttitta F. Merlo G. et al. p53 alterations in non-small cell lung cancers correlated with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res 1993;53:2864-2851
19 Harima Y. Harima K, Shikata N. Oka A. Ohnishi T, Tanaka Y. Bax and bcl-2 expressions predict response to radiotherapy in human cervical cancer. J Cancer Res Clin Oncol 1998;124:503-510   DOI   ScienceOn
20 Eifel PJ. Morris M, Wharton JT. Oswald MJ. The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1994;29:9-16   DOI   ScienceOn
21 Chittenden T. Harrington EA. O'Connor R. et al. Induction of apoptosis of the Bcl-2 homologue Bak. Nature 1995;374:733-736   DOI   ScienceOn
22 Halder S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994;54:2095-2097
23 Kainz C. Kohlberger P. Gitsch G. Sliutz G. Breitenecker G. Reinthaller A. Mutant p53 in patients with invasive cervical cancer stage IB to IIB. Gynecol Oncol 1995;57:212-214   DOI   ScienceOn
24 Oka K. Nakano T. Arai T. p53CM1 expression is not associated with prognosis in uterine cervical carcinoma. Cancer 1993;72:160-164   DOI   PUBMED   ScienceOn
25 Mukherjee G, Freeman A. Moore R, et al. Biologic factors and response to radiotherapy in carcinoma of the cervix. Int J Gynecol Cancer 2001:11:187-193   DOI   ScienceOn
26 Oltvai ZN, Milliman CL, Korsmever SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-619   DOI   PUBMED   ScienceOn
27 Miyashita T, Krajewski S, Kraiewska M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799-1805
28 Tjalma WA, Weyler JJ. Bogers JJ, et al. The importance of biological factors (bcl-2, bax, p53, PCNA, MI, HPV and angiogenesis) in invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol 2001;97:223-230   DOI   ScienceOn
29 Lipponen P, Pietilainen T, Kosma VM, Aaltomaa S, Eskelinen M, Syrianen K. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with a favourable prognosis. J Pathol 1995;177:49-55   DOI   ScienceOn
30 Stehman FB, Bundy BN, Disasia PJ, Keys HM, Larson JE. Fowler WC. Carcinoma of the cervix treated with radiation therapy. I. A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer 1991;67:2776-2785   DOI   PUBMED   ScienceOn
31 Awwad S, Jaros E, Somes J, Lunec J. P53 overexpressian in head and neck carcinoma and radiotherapy results. Int J Radiat Oncol Biol Phys 1996;34:323-332   DOI   ScienceOn
32 Kim HJ. Kim WC. Lee MJ. Kim CS. Song ES. Loh JK. Comparison of the result of radiation alone and radiation with daily low dose cisplatin in management of locally advanced cervical cancer. J Korea Soc Ther Radiol Oncol 2004;22:200-207
33 EI-Deiry WS, Harper JW, O'Connor PM, et al. WAF/ CIPI in p53-mediated G1 arrest and apoptosis. Cancer Res 1994:54:1169-1174
34 Iwava K, Tsuda H, Hiraide H, et al. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 1991;82:835-840   DOI
35 Holm R. Skomedal H. Helland P. Kristensen G. Borresen AL. Nesland JM. Immunohistochemical analysis of p53 protein overexpression in normal. premalignant. and malignant tissue of the cervix uteri. J Pathol 1993;169:21-26   DOI   ScienceOn
36 Kristensen GB. Abeler VM. Risberg B. Trope C. Bryne M. Tumor size. depth of invasion and grading of the invasive tumor front are the main prognostic factors in early squamous cell cervical carcinoma. Gynecol Oncol 1999;74:245-251   DOI   ScienceOn
37 Hall PA. Lane DP. P53 in tumour pathology: can we trust immunohistochemistry?-Revisited! J Pathol 1994;172:1-4   DOI   ScienceOn
38 Werness BA. Levine AJ. Howley PM. Association of human papillomavirus type 16 and 18 E6 proteins with p53. Science 1990;248:76-79   DOI   PUBMED
39 Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-849   DOI   ScienceOn
40 Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997;275:1129-1132   DOI   PUBMED   ScienceOn
41 Tjalma W, De Cuyper E, Weyler J, et al. Expression of bcl-2 in invasive and in situ carcinoma of the uterine cervix. Am J Obstet Gynecol 1998;178:113-117   DOI   PUBMED   ScienceOn
42 Ishikawa H, Mitsuhashi N, Sakurai H, Maebayashi K, Niibe H. The effects of p53 status and human papillomavirus infection on the clinical outcome of patients with stage IIIB cervical carcinoma treated with radiation therapy alone. Cancer 2001;91:80-89   DOI   PUBMED   ScienceOn
43 Ebara T, Mitsuhashi N, Saito Y, et al. Prognostic significance of immunohistochemically detected p53 protein expression in stage IIIB squamous cell carcinoma of the uterine cervix treated with radiation therapy alone. Gynecol Oncol 1996;63:216-218   DOI   ScienceOn
44 Chiou SK, Rao I, White E. Bcl-2 blocks p53-dependent apoptosis. Mol Cell Biol 1994;14:2556-2563   DOI   ScienceOn
45 Henriksen R, Wilander E, Oberg K. Expression and prognostic significance of Bcl-2 in ovarian tumors. Br J Cancer 1995;72:1324-1329   DOI   ScienceOn
46 Ohara K. Tanaka YO. Tsunoda. et al. Nonoperative assessment of nodal status for locally advanced cervical squamous cell carcinoma treated by radiotherapy with regard to patterns of treatment failure. Int J Radiat Oncol Biol Phys 2003;55:354-361   DOI   ScienceOn
47 Diebold J, Baretton G, Felchner M, et al. bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol 1996;105:341-349   DOI
48 2002 Annual Report of the Korea Central Cancer Registry, Ministry of Health and Welfare Republic of Korea
49 Isobe M, Emanuel BS, Givol D, Oren M, Croce CM. Location of gene for human p53 tumour antigen to band 17p13. Nature 1986;320:84-85   DOI   ScienceOn
50 Hall PA, Meek D, Lane DP. p53-integrating the complexity. J Pathol 1996;180:1-5   DOI   ScienceOn
51 Crawford RA, Caldwell C. Iles RK. Lowe D. Shepherd JH. Chard T. Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer. Br J Cancer 1998;78:210-214   DOI   ScienceOn
52 Skirnisdottir I. Seidal T. Gerdin E. Sorbe B. The prognostic importance of p53. bcl-2. and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy. Int J Gynecol Cancer 2002;12:265-276   DOI   ScienceOn
53 Lipponen PK, Aaltomaa S, Eskelinen M. Expression of the apoptosis suppressing bcl-2 protein in transitional cell bladder tumors. Histopathology 1996;28:135-140   DOI   PUBMED
54 Spafford M F, Koeppe J, Pan Z, Archer PG, Mevers AD, Franklin WA. Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1996;122:627-632   DOI   ScienceOn
55 Jain D, Srinivasan R, Patel FD, Kumari Gupta S. Evaluation of p53 and Bcl-2 expression as prognostic marker in invasive cervical carcinoma stage IIb/III patients treated by radiotherapy. Gynecol Oncol 2002;88:22-28   DOI   ScienceOn
56 Toita T, Nakano M. Higashi M. Sakumoto K, Kanazawa K. Prognostic value of cervical size and pelvic lymph node status assessed by computed tomography for patients with uterine cervical cancer treated by radical radiation therapy. Int J Radiat Oncol Biol Phys 1995;843-849   DOI   ScienceOn
57 Gitsch G. Kainz C. Joura E. Breitenecker G. Mutant p53 product in patients with stage III cervical cancer. Anticancer Res 1992;12:2241-2242